<DOC>
	<DOCNO>NCT02161770</DOCNO>
	<brief_summary>This 2-part study patient advance solid tumour . Part A investigate pharmacokinetics ( PK ) AZD9291 patient mild moderate hepatic impairment compare patient normal hepatic function ; Part B allow patient mild moderate hepatic impairment normal hepatic function , complete Part A , continue access AZD9291 PK phase provide additional safety data .</brief_summary>
	<brief_title>Study Assess Blood Levels Safety AZD9291 Patients With Advanced Solid Tumours Normal Liver Function Mild Moderate Liver Impairment</brief_title>
	<detailed_description />
	<mesh_term>Osimertinib</mesh_term>
	<criteria>For inclusion study patient hepatic impairment , follow criterion must meet : 1 . Patients must stable chronic hepatic impairment least 2 week prior Day 1 , see Section 4.1.1 . Patients hepatic metastasis and/or HCC eligible study , provide hepatic metastasis HCC sole reason change liver function satisfy criterion mild moderate hepatic impairment define Child Pugh criterion . Patients must globally impair hepatic function participate study . For inclusion study patient normal hepatic function , follow criterion must meet : 1 . Negative result serum hepatitis B surface antigen hepatitis C antibody 2 . Total bilirubin less equal to1.5 x institutional ULN , albumin prothrombin time within normal limit must ascites ( unless relate disease study ) encephalopathy . 3 . AST ALT less equal to2.5 x institutional ULN unless liver metastasis present case must less equal to5 x ULN . All patient must fulfil follow criterion : 1 . Male female , age least 18 year . 2 . Histological , appropriate , cytological confirmation malignant solid tumour refractory resistant standard therapy suitable effective standard therapy exist . Tumours inhibition EGFR pathway consider relevant Investigator mandate encourage . 3 . ECOG performance status less equal to2 . 4 . Patients must life expectancy great equal to12 week , estimate time screen . 5 . Females use adequate contraceptive measure must negative pregnancy test prior start dose childbearing potential must evidence nonchildbearing potential fulfil one follow criterion screen : postmenopausal define age 50 year amenorrhoeic least 12 month follow cessation exogenous hormonal treatment ; woman 50 year old would consider postmenopausal amenorrheic 12 month follow cessation exogenous hormonal treatment LH FSH level postmenopausal range institution ; documentation irreversible surgical sterilisation hysterectomy , bilateral oophorectomy bilateral salpingectomy tubal ligation 6 . Male patient willing use barrier contraception , ie , condom , 6 month last study drug take . Exclusion criterion : 1 . Participation another clinical study IP last 14 day ( long period depend defined characteristic agent use ) . 2 . Treatment previous 3 month dose study drug know welldefined potential fulminant hepatotoxicity ( eg , halothane methotrexate ) . 3 . Treatment follow : EGFR TKI w/in 8 day approximately 5x halflife , whichever longer , first dose study treatment ; Any cytotoxic chemotherapy , investigational agent anticancer drug w/in 14 day first dose study treatment ; Major surgery ( exclude placement vascular access ) w/in 4 week first dose ; Radiotherapy limit field radiation palliation within 1 week first dose study treatment , exception patient receive radiation 30 % bone marrow wide field radiation must complete within 4 week first dose study treatment ; Patients currently receive ( unable stop use prior receiving first dose study treatment ) medication herbal supplement know potent inhibitor CYP3A4 ( least 1 week prior ) potent inducer CYP3A4 ( least 3 week prior ) ( Appendix H ) . All patient Part B continue access must try avoid concomitant use medication , herbal supplement and/or ingestion food know potent inducer/inhibitory effect CYP3A4 ( Appendix H ) . 4 . Any unresolved toxicity prior therapy great CTCAE Grade 1 time start study treatment exception alopecia Grade 2 prior platinumtherapy relate neuropathy . 5 . Any intake grapefruit , grapefruit juice , Seville oranges , Seville orange marmalade , product contain grapefruit Seville oranges within 7 day first administration IP final PK sample collection Day 22 . 6 . Spinal cord compression brain metastasis unless asymptomatic , stable require steroid least 4 week prior start study treatment . 7 . Any evidence severe uncontrolled systemic disease , include uncontrolled hypertension active bleeding diatheses , Investigator 's opinion make undesirable patient participate study would jeopardise compliance protocol , active infection include hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) . Screening chronic condition require . 8 . Inadequate bone marrow reserve organ function demonstrate follow laboratory value : ANCless than1.5x10.9/L ; platelet count less than100x10.9/L ; haemoglobinless than90 g/L ; Creatinine great than1.5 x institutional ULN concurrent creatinine clearance less than50 mL/min ( measure calculate CockcroftGault formula ) ; confirmation creatinine clearance require creatinine great than1.5 x institutional ULN . 9 . Any following cardiac criterion : Mean rest correct QT interval correct heart rate use Fridericia 's correction factor ( QTcF ) great than470 msec obtain 3 ECGs ; Any clinically important abnormality rhythm , conduction morphology rest ECG eg , complete leave bundle branch block , third degree heart block , second degree heart block , PR interval great than250 msec ; Any factor increase risk QTc prolongation risk arrhythmic event heart failure , hypokalaemia , congenital long QT syndrome , family history long QT syndrome unexplained sudden death 40 year age concomitant medication know prolong QT interval . 10 . Patients unable swallow oral medication patient GI disorder significant GI resection likely interfere absorption AZD9291 . 11 . Past medical history interstitial lung disease ( ILD ) , druginduced ILD , radiation pneumonitis require steroid treatment , evidence clinically active ILD . 12 . Women breastfeed . 13 . Patients know hypersensitivity AZD9291 excipients . Patients normal hepatic function history presence hepatic disease know interfere absorption , distribution , metabolism excretion AZD9291 . Patients mild moderate hepatic function enter follow fulfil : 1 . Patients hepatic encephalopathy within last 4 week prior Day 1 . 2 . Fluctuating rapidly deteriorate hepatic function indicate widely vary worsen clinical and/or laboratory sign hepatic impairment within screen period . 3 . Presence acute liver disease cause drug toxicity infection . 4 . Severe portal hypertension surgical portosystemic shunt . 5 . Biliary obstruction cause hepatic impairment relate parenchymal disorder and/or disease liver . 6 . Oesophageal variceal bleeding within past 2 month . 7 . Anticoagulant therapy warfarin related coumadine.NOTE : Preferred format include list inclusion exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>oncology , cancer , neoplasm , anticancer drug , pharmacokinetics , area curve , AZD9291 , solid tumour , mild hepatic impairment , moderate hepatic impairment</keyword>
</DOC>